HCW Biologics Inc. (HCWB)
1.17
+0.05
(+4.46%)
USD |
NASDAQ |
Oct 23, 16:00
1.14
-0.03
(-2.56%)
After-Hours: 20:00
HCW Biologics Enterprise Value : 7.713M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 7.713M |
| October 22, 2026 | 7.632M |
| October 21, 2026 | 7.696M |
| October 20, 2026 | 7.713M |
| October 19, 2026 | 7.810M |
| October 16, 2026 | 7.826M |
| October 15, 2026 | 7.810M |
| October 14, 2026 | 7.713M |
| October 13, 2026 | 7.858M |
| October 12, 2026 | 8.214M |
| October 09, 2026 | 8.408M |
| October 08, 2026 | 8.295M |
| October 07, 2026 | 8.344M |
| October 06, 2026 | 8.360M |
| October 05, 2026 | 8.473M |
| October 02, 2026 | 8.538M |
| October 01, 2026 | 8.554M |
| September 30, 2026 | 8.586M |
| September 29, 2026 | 8.651M |
| September 28, 2026 | 8.764M |
| September 25, 2026 | 8.942M |
| September 24, 2026 | 9.039M |
| September 23, 2026 | 8.505M |
| September 22, 2026 | 8.748M |
| September 21, 2026 | 8.910M |
| Date | Value |
|---|---|
| September 18, 2026 | 8.845M |
| September 17, 2026 | 8.974M |
| September 16, 2026 | 9.072M |
| September 15, 2026 | 9.136M |
| September 14, 2026 | 9.379M |
| September 11, 2026 | 9.444M |
| September 10, 2026 | 9.751M |
| September 09, 2026 | 9.799M |
| September 08, 2026 | 9.880M |
| September 04, 2026 | 10.58M |
| September 03, 2026 | 10.46M |
| September 02, 2026 | 11.25M |
| September 01, 2026 | 11.40M |
| August 31, 2026 | 11.63M |
| August 28, 2026 | 11.37M |
| August 27, 2026 | 10.95M |
| August 26, 2026 | 10.19M |
| August 25, 2026 | 10.03M |
| August 24, 2026 | 9.557M |
| August 21, 2026 | 9.346M |
| August 20, 2026 | 9.249M |
| August 19, 2026 | 9.541M |
| August 18, 2026 | 9.266M |
| August 17, 2026 | 9.896M |
| August 14, 2026 | 10.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.37M |
| Revenue (Quarterly) | 0.1356M |
| Total Expenses (Quarterly) | 15.51M |
| EPS Diluted (Quarterly) | -11.58 |
| Gross Profit Margin (Quarterly) | -163.0% |
| Profit Margin (Quarterly) | -11.34K% |
| Earnings Yield | -2.43K% |
| Normalized Earnings Yield | -2637.90 |